Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study

Sophie Cousin, Jean-Yves Blay, Irene Braña Garcia, Johann S de Bono, Christophe Le Tourneau, Victor Moreno, Jose Trigo, Christine L Hann, Arun A Azad, Seock-Ah Im, Philippe A Cassier, Christopher A French, Antoine Italiano, Vicki L Keedy, Ruth Plummer, Marie-Paule Sablin, Matthew L Hemming, Geraldine Ferron-Brady, Anastasia Wyce, Ahmed Khaled, Antara Datta, Shawn W Foley, Michael T McCabe, Yuehui Wu, Thierry Horner, Brandon E Kremer, Arindam Dhar, Peter J O'Dwyer, Geoffrey I Shapiro, Sarina A Piha-Paul, Sophie Cousin, Jean-Yves Blay, Irene Braña Garcia, Johann S de Bono, Christophe Le Tourneau, Victor Moreno, Jose Trigo, Christine L Hann, Arun A Azad, Seock-Ah Im, Philippe A Cassier, Christopher A French, Antoine Italiano, Vicki L Keedy, Ruth Plummer, Marie-Paule Sablin, Matthew L Hemming, Geraldine Ferron-Brady, Anastasia Wyce, Ahmed Khaled, Antara Datta, Shawn W Foley, Michael T McCabe, Yuehui Wu, Thierry Horner, Brandon E Kremer, Arindam Dhar, Peter J O'Dwyer, Geoffrey I Shapiro, Sarina A Piha-Paul

Abstract

Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg once daily dose of the besylate formulation of molibresib as the recommended Phase 2 dose (RP2D). Here we present the results of Part 2 of our study, investigating safety, pharmacokinetics, pharmacodynamics and clinical activity of molibresib at the RP2D for nuclear protein in testis carcinoma (NC), small cell lung cancer, castration-resistant prostate cancer (CRPC), triple-negative breast cancer, estrogen receptor-positive breast cancer and gastrointestinal stromal tumor. The primary safety endpoints were incidence of adverse events (AEs) and serious AEs; the primary efficacy endpoint was overall response rate. Secondary endpoints included plasma concentrations and gene set enrichment analysis (GSEA). Molibresib 75 mg once daily demonstrated no unexpected toxicities. The most common treatment-related AEs (any grade) were thrombocytopenia (64%), nausea (43%) and decreased appetite (37%); 83% of patients required dose interruptions and 29% required dose reductions due to AEs. Antitumor activity was observed in NC and CRPC (one confirmed partial response each, with observed reductions in tumor size), although predefined clinically meaningful response rates were not met for any tumor type. Total active moiety median plasma concentrations after single and repeated administration were similar across tumor cohorts. GSEA revealed that gene expression changes with molibresib varied by patient, response status and tumor type. Investigations into combinatorial approaches that use BET inhibition to eliminate resistance to other targeted therapies are warranted.

Trial registration: ClinicalTrials.gov NCT01587703.

Keywords: BET inhibitor; NUT carcinoma; castration-resistant prostate cancer; molibresib.

© 2021 UICC.

References

REFERENCES

    1. Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. Expert Rev Mol Med. 2011;13:e29.
    1. Mujtaba S, Zeng L, Zhou MM. Structure and acetyl-lysine recognition of the bromodomain. Oncogene. 2007;26(37):5521-5527.
    1. Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149(1):214-231.
    1. Dey A, Nishiyama A, Karpova T, McNally J, Ozato K. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol Biol Cell. 2009;20(23):4899-4909.
    1. Yang Z, He N, Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol Cell Biol. 2008;28(3):967-976.
    1. Manzotti G, Ciarrocchi A, Sancisi V. Inhibition of BET proteins and histone deacetylase (HDACs): crossing roads in cancer therapy. Cancers (Basel). 2019;11(3):304.
    1. Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014;4(6):a014241.
    1. French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol. 2004;22(20):4135-4139.
    1. French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003;63(2):304-307.
    1. French CA, Ramirez CL, Kolmakova J, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2008;27(15):2237-2242.
    1. French CA, Rahman S, Walsh EM, et al. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov. 2014;4(8):928-941.
    1. Grayson AR, Walsh EM, Cameron MJ, et al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene. 2014;33(13):1736-1742.
    1. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-1073.
    1. Stathis A, Zucca E, Bekradda M, et al. Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discov. 2016;6(5):492-500.
    1. Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327):1119-1123.
    1. Wyce A, Soden P, Felitsky DJ, et al. Mechanism-based combination strategies for BET inhibitors in NUT midline carcinoma. Paper presented at: American Association for Cancer Research Annual Meeting; 2016; New Orleans, LA.
    1. Wyce A, Matteo JJ, Foley SW, et al. MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers. Oncogenesis. 2018;7(4):35.
    1. Wyce A, Degenhardt Y, Bai Y, et al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget. 2013;4(12):2419-2429.
    1. Asangani IA, Dommeti VL, Wang X, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510(7504):278-282.
    1. Zhang D, Leal AS, Carapellucci S, Zydeck K, Sporn MB, Liby KT. Chemoprevention of preclinical breast and lung cancer with the bromodomain inhibitor I-BET 762. Cancer Prev Res (Phila). 2018;11(3):143-156.
    1. Ocana A, Nieto-Jimenez C, Pandiella A. BET inhibitors as novel therapeutic agents in breast cancer. Oncotarget. 2017;8(41):71285-71291.
    1. Stuhlmiller TJ, Miller SM, Zawistowski JS, et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep. 2015;11(3):390-404.
    1. Hemming ML, Lawlor MA, Andersen JL, et al. Enhancer domains in gastrointestinal stromal tumor regulate KIT expression and are targetable by BET bromodomain inhibition. Cancer Res. 2019;79(5):994-1009.
    1. Piha-Paul SA, Hann CL, French CA, et al. Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors. JNCI Canc Spectr. 2019;4(2):pkz093.
    1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
    1. National Cancer Institute. Common Technology Criteria for Adverse Events version 4.0; 2009. . Accessed May 21, 2020.
    1. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.
    1. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
    1. Wang L, Nie J, Sicotte H, et al. Measure transcript integrity using RNA-seq data. BMC Bioinform. 2016;17:58.
    1. Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. Bioinformatics. 2012;28(16):2184-2185.
    1. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417-419.
    1. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
    1. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739-1740.
    1. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417-425.
    1. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
    1. Wickham H. ggplot2: Elegant Graphics for Data Analysis [software available at ]. New York, NY: Springer-Verlag; 2016.
    1. Kolde R. pheatmap: Pretty heatmaps; 2019. . Accessed January 5, 2021.
    1. Krishnatry AS, Voelkner A, Dhar A, Prohn M, Ferron-Brady G. Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: a semimechanistic autoinduction model. CPT Pharmacometrics Syst Pharmacol. 2021;10:709-722. doi:10.1002/psp4.12639
    1. Lin X, Huang X, Uziel T, et al. HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues. Mol Cancer Ther. 2017;16(2):388-396.
    1. Xu Y, Vakoc CR. Targeting cancer cells with BET bromodomain inhibitors. Cold Spring Harb Perspect Med. 2017;7(7):a026674.
    1. EU Optimal Use of Blood Project Partners. Manual of Optimal Blood Use; 2010.
    1. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205-213.
    1. Shu S, Polyak K. BET bromodomain proteins as cancer therapeutic targets. Cold Spring Harb Symp Quant Biol. 2016;81:123-129.
    1. Lewin J, Soria JC, Stathis A, et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol. 2018;36(30):3007-3014.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera